compounded glp-1 risks Safe use of GLP products Compounding, Peptides, and GLP-1s: Opportunities

Any concerning cognitive symptoms warrant clinical evaluation to exclude other causes, and the risk-benefit balance of continuing GLP-1 therapy should be individually assessed

For example, a literature review performed in 2024 found only two case reports of GLP-1 RAs for treating HS that met the inclusion criteria

It lives in the body too

Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C (2008) Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults

The MHRA (Medicines and Healthcare products Regulatory Authority) continues to monitor the safety profile of semaglutide, including any emerging adverse effects reported by patients and healthcare professionals